TGM2 and breast cancer: Consistent with these findings, analysis of differential TG2 expression alone could not distinguish patient survival times, but since TG2 is known to crosslink FN in the ECM we analyzed breast cancer patient survival times based on the differential expression of both FN and TGM218.